Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.8650
-0.0060-0.69%
Post-market: 0.87190.0069+0.80%19:01 EDT
Volume:7.11M
Turnover:6.10M
Market Cap:239.70M
PE:-7.78
High:0.8885
Open:0.8880
Low:0.8400
Close:0.8710
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:1.34
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:9.58
PE(LYR):-41.62

Loading ...

Akebia Grants New Hire Stock Options for 8,400 Shares Under NASDAQ Inducement Plan

Reuters
·
Yesterday

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Scynexis Names Akebia CMO Steven K. Burke to Board

Reuters
·
Sep 22

Akebia Therapeutics Price Target Maintained with a $4.00/Share by BTIG

Dow Jones
·
Sep 15

Akebia Doses First Patient in Phase 2 Ebribafusp Trial for Rare Complement-Mediated Kidney Diseases

Reuters
·
Sep 14

Akebia Therapeutics - Initial Data from Phase 2 Ebribafusp Trial Expected in 2027

THOMSON REUTERS
·
Sep 14

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

THOMSON REUTERS
·
Sep 14

Akebia Therapeutics Initiated at Buy by WestPark Capital

Dow Jones
·
Sep 08

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

Akebia Grants New Hire Stock Options for 8,400 Shares at $0.92 Each

Reuters
·
Sep 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 02

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

GlobeNewswire
·
Sep 01

Akebia Therapeutics Cut to Market Perform from Outperform by Leerink Partners

Dow Jones
·
Aug 08

Akebia downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Aug 07

Akebia Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Akebia Q2 FY26 Turns to Net Loss of $8.9 Million; Revenue Falls 21.44% to $49.1 Million

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate

Benzinga Earnings
·
Aug 06

Akebia Therapeutics Inc Expected to Post a Loss of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Akebia Grants 2 New Hires Options for 61,000 Shares at $1.32 Each

Reuters
·
Aug 04